{"symbol":"LLY","fiscalQuarter":"Q4-2022","reportDate":"2023-02-02","reportTime":"BMO","status":"reported","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q4-2022","postBrief":{"headline":"Eli Lilly Beats on EPS, Stock Down 3.46%","keyNumbers":[{"metric":"EPS","actual":"$2.09","expected":"N/A","surprise":"+14.27%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key therapeutic areas.","They expressed commitment to ongoing innovation despite market challenges."],"summary":"Management remains focused on advancing their pipeline and addressing market dynamics. They emphasized the importance of their product portfolio."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Eli Lilly's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 3.46%, likely due to a lack of revenue details and forward guidance, which may have left investors uncertain about future performance. The cautious tone from management suggests they are aware of challenges ahead but remain focused on their strategic goals.","metaDescription":"Eli Lilly (LLY) Q4 2022 earnings: EPS beat by 14.27%. Stock down 3.46%. Full breakdown."}}